Featured Product
This Week in Quality Digest Live
FDA Compliance Features
Del Williams
Options to address the risk of combustible dust explosions for NFPA 61 compliance
Doug Folsom
Unpatched vulnerabilities will become increasingly susceptible to cyberattacks
Del Williams
Mitigate risk, prevent safety issues by utilizing closed conveyor systems designed with sanitation in mind
Dirk Dusharme @ Quality Digest
Companies say they plan to pull some or all of their devices
Dirk Dusharme @ Quality Digest
First step, migrate your QMS to a cloud-based electronic quality management system

More Features

FDA Compliance News
Company’s first funding round will be used to accelerate product development for its QMS and MES SaaS offerings
Showcasing tech, solutions, and services at Gulfood Manufacturing 2022
Easy, reliable leak testing with methylene blue
Now is not the time to skip critical factory audits and supply chain assessments
Google Docs collaboration, more efficient management of quality deviations
Delivers time, cost, and efficiency savings while streamlining compliance activity
First trial module of learning tool focuses on ISO 9001 and is available now
Free education source for global medical device community
Good quality is adding an average of 11 percent to organizations’ revenue growth

More News

Quality Digest

FDA Compliance

PCMA Discourages Drug-Patent Extensions

Published: Wednesday, November 16, 2005 - 22:00

Citing concerns about bioterrorism preparedness, the Pharmaceutical Care Management Association has discouraged the extension of several prescription drug patents currently being discussed by Congress. Congress is currently being lobbied by drug companies to extend the patents on some drugs, but the PCMA reports that the results could be increased costs throughout the entire health-care system, as well as a decreased ability to prepare for bioterror attacks.

“PCMA believes that a strong national defense policy should include efforts to develop effective countermeasures to combat bioterrorism,” says Mark Merritt, PCMA president. “Regrettably, some of the drug-patent extension proposals being discussed raise serious concerns about the overall cost impact and whether they would even advance the goals of bioterrorism preparedness. At a time when private and public purchasers are looking to expand access to clinically proven, cost-effective drugs, brand-name drug extensions take us in exactly the wrong direction.”

Among the unanswered questions about brand-name drug extensions and bioterrorism preparedness include:

  • How much would drug-patent extensions increase prescription-drug costs for working families and seniors? How much would costs increase for private health-care purchasers, including unions, small businesses and large employers?
  • How much would consumers see their health benefits eroded or eliminated because of the costs associated with drug-patent extensions?
  • How much would drug-patent extensions increase costs and Part D premiums in the new Medicare prescription-drug benefit?
  • How would drug-patent extensions advance the goals of bioterrorism preparedness?

PCMA represents America’s pharmacy-benefit managers, who administer prescription drug plans to 200 million Americans. For more information, visit www.pcmanet.org.

Discuss

About The Author

Quality Digest’s picture

Quality Digest

For 40 years Quality Digest has been the go-to source for all things quality. Our newsletter, Quality Digest, shares expert commentary and relevant industry resources to assist our readers in their quest for continuous improvement. Our website includes every column and article from the newsletter since May 2009 as well as back issues of Quality Digest magazine to August 1995. We are committed to promoting a view wherein quality is not a niche, but an integral part of every phase of manufacturing and services.